166 related articles for article (PubMed ID: 9351544)
1. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.
Small EJ; Baron A; Bok R
Cancer; 1997 Nov; 80(9):1755-9. PubMed ID: 9351544
[TBL] [Abstract][Full Text] [Related]
2. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Small EJ; Baron AD; Fippin L; Apodaca D
J Urol; 1997 Apr; 157(4):1204-7. PubMed ID: 9120902
[TBL] [Abstract][Full Text] [Related]
3. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
[TBL] [Abstract][Full Text] [Related]
4. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer.
Small EJ; Srinivas S
Cancer; 1995 Oct; 76(8):1428-34. PubMed ID: 8620419
[TBL] [Abstract][Full Text] [Related]
5. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
Schellhammer PF; Venner P; Haas GP; Small EJ; Nieh PT; Seabaugh DR; Patterson AL; Klein E; Wajsman Z; Furr B; Chen Y; Kolvenbag GJ
J Urol; 1997 May; 157(5):1731-5. PubMed ID: 9112515
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Sartor AO; Tangen CM; Hussain MH; Eisenberger MA; Parab M; Fontana JA; Chapman RA; Mills GM; Raghavan D; Crawford ED;
Cancer; 2008 Jun; 112(11):2393-400. PubMed ID: 18383517
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer.
Argirovic Dj
Acta Chir Iugosl; 2005; 52(4):51-4. PubMed ID: 16673595
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance.
Paul R; Breul J
Drug Saf; 2000 Nov; 23(5):381-90. PubMed ID: 11085345
[TBL] [Abstract][Full Text] [Related]
12. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
Keizman D; Huang P; Carducci MA; Eisenberger MA
Prostate; 2012 Mar; 72(4):461-7. PubMed ID: 21688281
[TBL] [Abstract][Full Text] [Related]
13. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher HI; Kelly WK
J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
[TBL] [Abstract][Full Text] [Related]
14. Prolonged prostate-specific antigen response in flutamide withdrawal syndrome despite disease progression.
Longmore L; Foley JP; Rozanski TA; Higgins B; Thompson IM
South Med J; 1998 Jun; 91(6):573-5. PubMed ID: 9634122
[TBL] [Abstract][Full Text] [Related]
15. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate.
Akakura K; Akimoto S; Furuya Y; Ito H
Eur Urol; 1998; 33(6):567-71. PubMed ID: 9743699
[TBL] [Abstract][Full Text] [Related]
16. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
Ryan CJ; Halabi S; Ou SS; Vogelzang NJ; Kantoff P; Small EJ
Clin Cancer Res; 2007 Apr; 13(7):2030-7. PubMed ID: 17404083
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore.
Ngo LS; Yeo A; Wong AS; Tay MH
Ann Acad Med Singap; 2007 Oct; 36(10):811-4. PubMed ID: 17987231
[TBL] [Abstract][Full Text] [Related]
18. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.
Wilkinson S; Chodak G
Eur Urol; 2004 May; 45(5):581-4; discussion 585. PubMed ID: 15082199
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.
Dawson NA; Cooper MR; Figg WD; Headlee DJ; Thibault A; Bergan RC; Steinberg SM; Sausville EA; Myers CE; Sartor O
Cancer; 1995 Aug; 76(3):453-62. PubMed ID: 8625127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]